Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotyp...
Main Authors: | Esposito, Susanna, Principi, Nicola |
---|---|
Format: | Online |
Language: | English |
Published: |
Hindawi Publishing Corporation
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553318/ |
Similar Items
-
Use of 13-valent pneumococcal conjugate vaccine in children older than 5 years of age
by: Principi, Nicola, et al.
Published: (2014) -
13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017-03-01) -
Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine
by: Esposito, Susanna, et al.
Published: (2016) -
Pneumococcal vaccination in children with underlying conditions
by: Principi, Nicola, et al.
Published: (2015) -
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
by: Shiramoto, Masanari, et al.
Published: (2015)